Factors influencing innate immunity and vaccine responses in infancy

Philosophical Transactions of the Royal Society B: Biological Sciences

Volumn 370, Issue 1671, 2015, Pages

  Kampmann, Beate ^a,b   Jones, Christine E ^c  

^a MRC Unit   (Gambia)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

BCG vaccine; Immune ontogeny; Maternal immunization; Vaccine responses

Indexed keywords

IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; INFANT MORTALITY; ONTOGENY; VACCINATION;

VACCINE;

HUMAN; IMMUNOLOGY; INFANT; INNATE IMMUNITY; NEWBORN; PHYSIOLOGY;

HUMANS; IMMUNITY, INNATE; INFANT; INFANT, NEWBORN; VACCINES;

EID: 84929239345     PISSN: 09628436     EISSN: 14712970     Source Type: Journal    
DOI: 10.1098/rstb.2014.0148     Document Type: Review

References (40)

1. Koff WC, Burton DR, Johnson PR, Walker BD, King CR, Nabel GJ, Ahmed R, Bhan MK, Plotkin SA. 2013 Accelerating next-generation vaccine development for global disease prevention. Science 340, 1232910. (doi:10.1126/science.1232910)
2. Hill K, You D, Inoue M, Oestergaard MZ. 2012 Child mortality estimation: accelerated progress in reducing global child mortality, 1990–2010. PLoS Med. 9, e1001303. (doi:10.1371/journal.pmed.1001303)
3. Liu L et al. 2012 Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000. Lancet 379, 2151–2161. (doi:10.1016/S0140-6736(12)60560-1)
4. Lawn JE, Cousens S, Zupan J, Lancet Neonatal Survival Steering Team. 2005 4 million neonatal deaths: when? where? why? Lancet 365, 891–900. (doi:10.1016/S0140-6736(05)71048-5)
5. Waters D et al. 2011 Aetiology of communityacquired neonatal sepsis in low and middle income countries. J. Glob. Health 1, 154–170.
6. Kwambana BA, Barer MR, Bottomley C, Adegbola RA, Antonio M. 2011 Early acquisition and high nasopharyngeal co-colonisation by Streptococcus pneumoniae and three respiratory pathogens amongst Gambian new-borns and infants. BMC Infect. Dis. 11, 175. (doi:10.1186/1471-2334-11-175)
7. Lindsey B, Kampmann B, Jones C. 2013 Maternal immunization as a strategy to decrease susceptibility to infection in newborn infants. Curr. Opin. Infect. Dis. 26, 248–253. (doi:10.1097/QCO.0b013e3283607a58)
8. Levy O. 2007 Innate immunity of the newborn: basic mechanisms and clinical correlates. Nat. Rev. Immunol. 7, 379–390. (doi:10.1038/nri2075)
9. Burl S et al. 2011 Age-dependent maturation of Toll-like receptor-mediated cytokine responses in Gambian infants. PLoS ONE 6, e18185. (doi:10.1371/journal.pone.0018185)
10. Lisciandro JG et al. 2012 Ontogeny of Toll-like and NOD-like receptor-mediated innate immune responses in Papua New Guinean infants. PLoS ONE 7, e36793. (doi:10.1371/journal.pone.0036793)
11. Kollmann TR et al. 2009 Neonatal innate TLRmediated responses are distinct from those of adults. J Immunol. 183, 7150–7160. (doi:10.4049/jimmunol.0901481)
12. Kollmann TR. 2013 Variation between populations in the innate immune response to vaccine adjuvants. Front. Immunol. 4, 81. (doi:10.3389/fimmu.2013.00081)
13. Houghteling PD, Walker WA. 2015 Why is initial bacterial colonization of the intestine important to infants’ and children’s health? J. Pediatr. Gastroenterol. Nutr. 60, 294–307. (doi:10.1097/MPG.0000000000000597)
14. Kampmann B, Tena GN, Mzazi S, Eley B, Young DB, Levin M. 2004 Novel human in vitro system for evaluating antimycobacterial vaccines. Infect. Immun. 72, 6401–6407. (doi:10.1128/IAI.72.11.6401-6407.2004)
15. Lutwama F et al. 2014 Distinct T-cell responses when BCG vaccination is delayed from birth to 6 weeks of age in Ugandan infants. J. Infect. Dis. 209, 887–897. (doi:10.1093/infdis/jit570)
16. Burl S et al. 2010 Delaying bacillus Calmette–Guérin vaccination from birth to 4 1/2 months of age reduces postvaccination Th1 and IL-17 responses but leads to comparable mycobacterial responses at 9 months of age. J. Immunol. 185, 2620–2628.
17. Shey MS et al. 2014 Maturation of innate responses to mycobacteria over the first nine months of life. J. Immunol. 192, 4833–4843. (doi:10.4049/jimmunol.1400062)
18. Trunz BB, Fine P, Dye C. 2006 Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet 367, 1173–1180. (doi:10.1016/S0140-6736(06)68507-3)
19. Hur Y-G et al. 2014 Factors affecting immunogenicity of BCG in infants, a study in Malawi, The Gambia and the UK. BMC Infect. Dis. 14, 184. (doi:10.1186/1471-2334-14-184)
20. Smolen KK et al. 2014 Single-cell analysis of innate cytokine responses to pattern recognition receptor stimulation in children across four continents. J. Immunol. 193, 3003–3012. (doi:10.4049/jimmunol.1400895)
21. Hartgers FC, Obeng BB, Voskamp A, Larbi IA, Amoah AS, Luty AJF, Boakye D, Yazdanbakhsh M. 2008 Enhanced Toll-like receptor responsiveness associated with mitogen-activated protein kinase activation in Plasmodium falciparum-infected children. Infect. Immun. 76, 5149–5157. (doi:10.1128/IAI.01579-07)
22. Elliott AM et al. 2010 Effects of maternal and infant co-infections, and of maternal immunisation, on the infant response to BCG and tetanus immunisation. Vaccine 29, 247–255. (doi:10.1016/j.vaccine.2010.10.047)
23. Jones CE, Naidoo S, De Beer C, Esser M, Kampmann B, Hesseling AC. 2011 Maternal HIV infection and antibody responses against vaccinepreventable diseases in uninfected infants. J. Am. Med. Assoc. 305, 576–584. (doi:10.1001/jama.2011.100)
24. Jones CE, Hesseling AC, Tena-Coki NG, Scriba TJ, Chegou NN, Kidd M, Wilkinson RJ, Kampmann B. 2015 The impact of HIV exposure and maternal Mycobacterium tuberculosis infection on infant immune responses to bacille Calmette–Guérin vaccination. AIDS 29, 155–165. (doi:10.1097/QAD.0000000000000536)
25. Jones C, Pollock L, Barnett SM, Battersby A, Kampmann B. 2013 Specific antibodies against vaccine-preventable infections: a mother–infant cohort study. BMJ Open 3, e002473. (doi:10.1136/bmjopen-2012-002473)
26. Lindsey B, Jones C, Kampmann B. 2012 Bridging the gap: maternal immunisation as a means to reduce neonatal deaths from infectious diseases. Pathog. Glob. Health 106, 137–138. (doi:10.1179/204777312X13462106637684)
27. Khan R, Vandelaer J, Yakubu A, Raza AA, Zulu F. 2015 Maternal and neonatal tetanus elimination: from protecting women and newborns to protecting all. Int. J. Women’s Health 7, 171–180. (doi:10.2147/IJWH.S50539)
28. Amirthalingam G, Andrews N, Campbell H, Ribeiro S, Kara E, Donegan K, Fry NK, Miller E, Ramsay M. 2014 Effectiveness of maternal pertussis vaccination in England: an observational study. Lancet 384, 1521–1528. (doi:10.1016/S0140-6736(14)60686-3)
29. Dabrera G, Amirthalingam G, Andrews N, Campbell H, Ribeiro S, Kara E, Fry NK, Ramsay M. 2015 A case-control study to estimate the effectiveness of maternal pertussis vaccination in protecting newborn infants in England and Wales, 2012–2013. Clin. Infect. Dis. 60, 333–337. (doi:10.1093/cid/ciu821)
30. Jones C, Pollock L, Barnett SM, Battersby A, Kampmann B. 2014 The relationship between concentration of specific antibody at birth and subsequent response to primary immunization. Vaccine 32, 996–1002. (doi:10.1016/j.vaccine.2013.11.104)
31. Munoz FM et al. 2014 Safety and immunogenicity of tetanus diphtheria and acellular pertussis (Tdap) immunization during pregnancy in mothers and infants. J. Am. Med. Assoc. 311, 1760–1769. (doi:10.1001/jama.2014.3633)
32. Richards JL et al. 2013 Neonatal outcomes after antenatal influenza immunization during the 2009 H1N1 influenza pandemic: impact on preterm birth, birth weight, and small for gestational age birth. Clin. Infect. Dis. 56, 1216–1222. (doi:10.1093/cid/cit045)
33. Cáceres VM, Strebel PM, Sutter RW. 2000 Factors determining prevalence of maternal antibody to measles virus throughout infancy: a review. Clin. Infect. Dis. 31, 110–119. (doi:10.1086/313926)
34. Ota MOC et al. 2002 Influence of Mycobacterium bovis bacillus Calmette-Guérin on antibody and cytokine responses to human neonatal vaccination. J. Immunol. 168, 919–925. (doi:10.4049/jimmunol.168.2.919)
35. Freyne B, Marchant A, Curtis N. 2015 BCG-associated heterologous immunity, a historical perspective: intervention studies in animal models of infectious diseases. Trans. R. Soc. Trop. Med. Hyg. 109, 52–61. (doi:10.1093/trstmh/tru197)
36. Netea MG, van Crevel R. 2014 BCG-induced protection: effects on innate immune memory. Semin. Immunol. 26, 512–517. (doi:10.1016/j.smim.2014.09.006)
37. Ifrim DC et al. 2014 Trained immunity or tolerance: opposing functional programs induced in human monocytes after engagement of various pattern recognition receptors. Clin. Vacc. Immunol. 21, 534–545. (doi:10.1128/CVI.00688-13)
38. Newport MJ, Goetghebuer T, Weiss HA, Whittle H, Siegrist CA, Marchant A. 2004 Genetic regulation of immune responses to vaccines in early life. Genes and immunity. Nature 5, 122–129. (doi:10.1038/sj.gene.6364051)
39. Marchant A et al. 2006 Predominant influence of environmental determinants on the persistence and avidity maturation of antibody responses to vaccines in infants. J. Infect. Dis. 193, 1598–1605. (doi:10.1086/503775)
40. Mentzer AJ, O’Connor D, Pollard AJ, Hill AVS. 2015 Searching for the human genetic factors standing in the way of universally effective vaccines. Phil. Trans. R. Soc. B 370, 20140341. (doi:10.1098.rstb.2014.0341)